文献速递骨质疏松与代谢性骨病创伤骨科

中药使用与骨质疏松患者骨折风险的关联:一项基于人群的队列研究

Association of use of Chinese herbal medicines and the risk of fracture in patients with osteoporosis: a population-based cohort study.
PubMed 文献 · Osteoporos Int · 2019-02-05

该研究利用台湾全民健康保险研究数据库,纳入1998至2010年新诊断的250,699例20岁及以上骨质疏松患者,经倾向评分匹配后比较103,325例中药使用者与103,325例非使用者,随访至2012年底。结果显示中药使用者骨质疏松性骨折风险显著降低(调整HR 0.73;95%CI 0.70-0.75),使用超过730天者骨折风险降低54%。作者认为中药可整合入常规治疗以预防后续骨折。

要点

  • 骨质疏松患者使用中药与后续骨质疏松性骨折风险降低相关(调整HR 0.73;95%CI 0.70-0.75)。
  • 使用中药超过730天的患者骨折风险降低54%。
  • 多种常用中药及方剂与较低的骨折风险相关。

核心结论

  • 骨质疏松患者使用中药与较低的骨质疏松性骨折风险相关,提示可将中药整合入常规治疗以预防后续骨折。

研究设计与样本

  • 纵向队列研究,使用台湾全民健康保险研究数据库识别1998至2010年间新诊断的250,699例20岁及以上骨质疏松患者。
  • 招募103,325例骨质疏松发病后使用中药者为中药使用者,并按人口学特征和合并症经倾向评分匹配随机选取103,325例未使用中药者为对照。
  • 所有入组者随访至2012年底以记录骨质疏松性骨折发生率,采用Cox比例风险回归模型计算骨折风险的风险比(HR)。

主要发现

  • 15年随访期间,中药使用者中7208例和非使用者中11453例发生骨质疏松性骨折,发生率分别为每1000人年9.26和12.96。
  • 中药使用者较非使用者骨质疏松性骨折风险显著降低(调整HR 0.73;95%CI 0.70-0.75)。
  • 使用中药超过730天的患者骨折风险降低54%。
  • 部分常用中药如延胡索(Rhizoma Corydalis)、黄芩(Scutellaria Baicale)、桔梗(Platycodon grandifloras)、香附(Cyperus rotundus)、海螵蛸(Cuttlebone Sepium)及加味逍遥散、葛根汤、芍药甘草汤、独活寄生汤与较低的骨折风险相关。

关键数值与推荐

  • 中药使用者骨质疏松性骨折调整HR 0.73(95%CI 0.70-0.75),非使用者为参照。
  • 使用中药超过730天者骨折风险降低54%。
  • 中药使用者骨折发生率为每1000人年9.26,非使用者为每1000人年12.96。

临床怎么用

  • 作者认为中药使用与骨质疏松患者较低的骨折风险相关,提示可将中药整合入常规治疗以预防后续骨折。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: After utilizing a large population-based claims database and the application of propensity score match approach to reduce the confounding effects, we found that the use of Chinese herbal medicines (CHMs) was related to the lower risk of sequent osteoporotic fracture by 27% among the individuals with osteoporosis. The predominant effect was observed in those receiving CHMs for more than two years. INTRODUCTION: Osteoporosis (OS) is a highly disabling condition that can lead to fragility fracture, thus posing greater burdens of functional limitations for the affected individuals. It is unclear if the use of Chinese herbal medicines (CHMs) could reduce the risk of fracture due to OS. This study aimed to investigate the association of CHMs and the subsequent osteoporotic fracture risk among OS patients. METHODS: This longitudinal cohort study used the Taiwanese National Health Insurance Research Database to identify 250,699 newly diagnosed OS patients aged 20 years or older between 1998 and 2010. We recruited 103,325 CHM users following the onset of OS (CHM users) and randomly selected 103,325 subjects without CHM usage as controls (non-CHM users) by propensity score matching according to the demographic characteristics and comorbidities at enrollment. All enrollees were followed until the end of 2012 to record the incidence of osteoporotic fracture. We applied the Cox proportional hazard regression model to compute the hazard ratio (HR) of the risk of osteoporotic fracture. RESULTS: During the 15-year follow-up period, 7208 CHM users and 11,453 non-CHM users sustained osteoporotic fracture, with an incidence rate of 9.26 and 12.96, respectively, per 1000 person-years. We found that CHM users had a significantly reduced risk of osteoporotic fracture compared to non-CHM users (adjusted HR 0.73; 95% confidence interval [CI] = 0.70-0.75). Those treated with CHMs for longer than 730 days had a lower fracture risk by 54%. Some commonly used CHMs, such as Yan hu suo (Rhizoma Corydalis), Huang Qin (Scutellaria Baicale), Jie Geng (Platycodon grandifloras), Xiang Fu (Cyperus rotundus), Hai Piao Xiao (Cuttlebone Sepium), Jia-Wei-Xiao-Yao-San, Ge-Gen-Tang, Shao-Yao-Gan-Cao-Tang, and Du-Huo-Ji-Sheng-Tang, are related to the lower risk of fracture. CONCLUSIONS: The use of CHMs was associated with lower risk of osteoporotic fracture for OS patients, suggesting that it could be integrated into conventional therapy to prevent subsequent bone fracture.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Chen WJ, Livneh H, Hsieh MH, et al. Association of use of Chinese herbal medicines and the risk of fracture in patients with osteoporosis: a population-based cohort study. Osteoporos Int. 2019. PMID: 30721331. doi:10.1007/s00198-018-4789-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。